Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Jones Lang LaSalle Inc (JLL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Jones Lang LaSalle IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Jones Lang LaSalle Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Jones Lang LaSalle Inc trades at $361.02 (market cap $16.72B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.9× Jones Lang LaSalle Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.

JLLREGN
Market Cap
$16.72B$82.06B
Sector
Real EstateHealth
52-Week High
$373.24$812.27
52-Week Low
$280.16$555.51
Enterprise Value
$19.48B$76.77B
Dividend Yield
0.47%

Returns comparison

Trailing returns across standard periods

About Jones Lang LaSalle Inc

Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.

Read more on JLL

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN